thalidomide + etoposide + celecoxib

This appears to be a multi-agent oral antiangiogenic (metronomic) chemotherapy regimen used primarily in pediatric oncology. The search results indicate this combination is often used with cyclophosphamide and sometimes fenofibrate as part of a "5-drug" regimen, but I'll focus specifically on the three drugs you requested. ## Drug Information The combination of thalidomide + etoposide + celecoxib is an oral antiangiogenic regimen used in metronomic chemotherapy, particularly for pediatric patients with recurrent or progressive cancer. This regimen works through multiple mechanisms, with thalidomide and celecoxib providing antiangiogenic effects (stopping blood flow to tumors), while etoposide acts as a chemotherapeutic agent to directly target cancer cells[1][2]. In clinical trials, this combination has been administered with thalidomide given continuously, celecoxib given twice daily, and etoposide typically given in 21-day cycles, often alternating with cyclophosphamide[3]. The regimen has shown varying degrees of efficacy across different tumor types, with some promising results in certain brain tumors, particularly low-grade gliomas[5]. The treatment is generally well-tolerated, with the most common toxicities being hematologic (blood-related)[2][3]. In clinical trials, patients have been monitored for response over periods of approximately 27 weeks[2]. This combination has been studied in various pediatric cancers including high-grade glioma, ependymoma, low-grade glioma, bone tumors, medulloblastoma/primitive neuroectodermal tumor (PNET), leukemia, and neuroblastoma[2][6]. The canonical name for this combination would be "thalidomide + etoposide + celecoxib," as it represents a specific metronomic chemotherapy regimen rather than a branded combination product. It falls under the broader category of antiangiogenic metronomic chemotherapy approaches.